COMMUNIQUÉS West-GlobeNewswire

Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy
25/01/2024
– Participants treated with atacicept for 72 weeks showed consistent and sustained reductions in Gd-IgA1, hematuria, and UPCR, with stable eGFR over the duration of treatment – Placebo cohort participants who crossed [...]
Le KFSH&RC honore 25 scientifiques nommés dans le classement de Stanford parmi les 2 % des chercheurs les plus cités au monde
25/01/2024
RIYAD, Arabie Saoudite, 25 janv. 2024 (GLOBE NEWSWIRE) -- L’hôpital spécialisé et centre de recherche King Faisal (KFSH&RC) a honoré les 25 scientifiques ayant rejoint le prestigieux classement de l’Université de [...]
Detailed Analysis of BEXMAB Data Provides Insights into Patient Profiles of Responding HMA-Failed MDS Population
25/01/2024
TURKU, Finland and BOSTON, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company pursuing a CLEVER approach to reprogramming myeloid [...]
Nicox Provides Fourth Quarter 2023 Financial and Business Highlights
25/01/2024
Press Release Nicox Provides Fourth Quarter 2023 Financial and Business Highlights NCX 470 Phase 3 Denali clinical trial 75% randomized Net revenue €1.3 million for fourth quarter 2023 and €4.2 million for the full year [...]
Nicox : Résumé financier et point d’activité du quatrième trimestre 2023
25/01/2024
Communiqué de presse Nicox : Résumé financier et point d’activité du quatrième trimestre 2023 Randomisation de 75% des patients de l'étude clinique de phase 3 Denali sur le NCX 470 Chiffre d’affaires net de €1,3 million [...]
BioSenic presents new Phase 3 data on JTA-004 to treat severe osteoarthritis pain at the 2024 OARSI World Congress
25/01/2024
PRESS RELEASE BioSenic presents new Phase 3 data on JTA-004 to treat severe osteoarthritis pain at the 2024 OARSI World Congress Using a recently published approach to stratify patients with knee osteoarthritis, an [...]
BioSenic présente de nouvelles données de phase 3 sur JTA-004 pour le traitement de la douleur arthrosique sévère lors du congrès mondial de l'OARSI 2024
25/01/2024
COMMUNIQUE DE PRESSE BioSenic présente de nouvelles données de phase 3 sur JTA-004 pour le traitement de la douleur arthrosique sévère lors du congrès mondial de l'OARSI 2024 En utilisant une approche récemment publiée [...]
AbSolutions Med, Inc. Receives FDA Breakthrough Device Designation for its REBUILD™ Bioabsorbable Abdominal Wall Closure Device
25/01/2024
MOUNTAIN VIEW, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- AbSolutions Med, Inc., a privately held medical device company, announced today that the Food and Drug Administration (FDA) has granted Breakthrough Device [...]
Revive Therapeutics Ltd. Announces Offering of Up to $3 Million
24/01/2024
NOT FOR DISSEMINATION IN THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES AND DOES NOT CONSTITUTE AN OFFER OF THE SECURITIES DESCRIBED HEREIN TORONTO, Jan. 24, 2024 (GLOBE NEWSWIRE) -- REVIVE THERAPEUTICS [...]
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
24/01/2024
STAMFORD, Conn., Jan. 24, 2024 (GLOBE NEWSWIRE) -- GeneDx, a leader in delivering improved health outcomes through genomic and clinical insights, today announced that, effective as of January 23, 2024, the compensation [...]
Half-Year Review of Inventiva’s Liquidity Contract with Kepler Cheuvreux
24/01/2024
Daix (France), Long Island City (New York, United States), January 24, 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral [...]
Bilan semestriel du contrat de liquidité de la société Inventiva conclu avec Kepler Cheuvreux
24/01/2024
Daix (France), Long Island City (New York, Etats Unis), le 24 janvier 2024 – Inventiva (Euronext Paris and Nasdaq: IVA) (la "Société"), société biopharmaceutique spécialisée dans le développement clinique de petites [...]
Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
24/01/2024
FARMINGTON HILLS, Mich., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies [...]
Tourmaline Bio Announces Proposed Public Offering of Common Stock
24/01/2024
NEW YORK, Jan. 24, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (“Tourmaline”) (Nasdaq: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of [...]
23andMe to Report FY2024 Third Quarter Financial Results
24/01/2024
SOUTH SAN FRANCISCO, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and [...]
ClearPoint Neuro Announces Installation and First Procedure Using the ClearPoint Prism® Neuro Laser Therapy System and Navigation System at Kaleida Health in Buffalo
24/01/2024
SOLANA BEACH, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global device, cell, and gene therapy-enabling company offering precise navigation to the brain and spine [...]
ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2024
24/01/2024
Year-over-year revenue grows 12% , operating profit down 2% , non-GAAP operating profit up 20% Resumed share repurchase program, repurchased $50 million during quarter Note: A webcast of ResMed’s conference call will be [...]
UPDATE -- Visory Health Announces The Kroger Company As Preferred Pharmacy
24/01/2024
The prescription discount card has helped customers save over $5 billion on prescriptions at over 35,000 pharmacies nationwide ORLANDO, Fla., Jan. 24, 2024 (GLOBE NEWSWIRE) -- Visory Health , a women-led, patient-first [...]
Transparency Notifications from Shareholders
24/01/2024
PRESS RELEASE REGULATED INFORMATION 24 January 2024, 06:00 pm CET Ghent, Belgium – 24 January 2024 – Sequana Medical NV (Euronext Brussels: SEQUA) (the " Company " or " Sequana Medical "), a pioneer in the treatment of [...]

Pages